SHANGHAI ALLIST PHARMACEUTICALS CO., LTDSS

SHANGHAI ALLIST PHARMACEUTICALS CO., LTD

58.73CNYD
+0.61+1.05%
At close at Jan 10, 08:50 UTC
CNY
No trades
See on Supercharts

688578 fundamentals

SHANGHAI ALLIST PHARMACEUTICALS CO., LTD financial statements, including revenue, expenses, profit, and loss

The total revenue of 688578 for the last quarter is 942.80 M CNY, and it's 14.75% higher compared to the previous quarter. The net income of Q3 24 is 406.81 M CNY.

Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
‪‪1.00 B‬‬
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: CNY
Q4 '19
Dec 2019
Q1 '20
Mar 2020
Q2 '20
Jun 2020
Q3 '20
Sep 2020
Q4 '20
Dec 2020
Q1 '21
Mar 2021
Q2 '21
Jun 2021
Q3 '21
Sep 2021
Q4 '21
Dec 2021
Q1 '22
Mar 2022
Q2 '22
Jun 2022
Q3 '22
Sep 2022
Q4 '22
Dec 2022
Q1 '23
Mar 2023
Q2 '23
Jun 2023
Q3 '23
Sep 2023
Q4 '23
Dec 2023
Q1 '24
Mar 2024
Q2 '24
Jun 2024
Q3 '24
Sep 2024
TTM
Total revenueYoY growth
‪‪270.28 M‬‬
+549.72%
‪‪273.18 M‬‬
+147.03%
‪‪466.04 M‬‬
+147.29%
‪‪591.05 M‬‬
+172.92%
‪‪661.30 M‬‬
+144.67%
‪‪732.31 M‬‬
+168.07%
‪‪821.62 M‬‬
+76.30%
‪‪942.80 M‬‬
+59.51%
‪‪3.16 B‬‬
‪‪−15.18 M‬‬
‪‪−16.84 M‬‬
‪‪−29.25 M‬‬
‪‪−32.41 M‬‬
‪‪−36.21 M‬‬
‪‪−42.71 M‬‬
‪‪−43.70 M‬‬
‪‪−37.50 M‬‬
‪‪−160.12 M‬‬
Gross profitYoY growth
‪‪255.10 M‬‬
+685.53%
‪‪256.34 M‬‬
+151.08%
‪‪436.79 M‬‬
+145.83%
‪‪558.64 M‬‬
+176.73%
‪‪625.10 M‬‬
+145.04%
‪‪689.60 M‬‬
+169.01%
‪‪777.93 M‬‬
+78.10%
‪‪905.29 M‬‬
+62.05%
‪‪3.03 B‬‬
‪‪−203.01 M‬‬
‪‪−239.38 M‬‬
‪‪−282.30 M‬‬
‪‪−371.71 M‬‬
‪‪−434.14 M‬‬
‪‪−403.79 M‬‬
‪‪−400.16 M‬‬
‪‪−483.42 M‬‬
‪‪−1.72 B‬‬
‪‪52.09 M‬‬
‪‪16.96 M‬‬
‪‪154.49 M‬‬
+529.48%
‪‪186.93 M‬‬
+17,518.66%
‪‪190.96 M‬‬
+266.58%
‪‪285.81 M‬‬
+1,585.25%
‪‪377.76 M‬‬
+144.51%
‪‪421.87 M‬‬
+125.68%
‪‪1.28 B‬‬
‪‪19.97 M‬‬
‪‪19.72 M‬‬
‪‪28.33 M‬‬
‪‪20.11 M‬‬
‪‪38.71 M‬‬
‪‪28.09 M‬‬
‪‪20.47 M‬‬
‪‪57.08 M‬‬
‪‪144.35 M‬‬
Pretax incomeYoY growth
‪‪72.07 M‬‬
‪‪36.68 M‬‬
‪‪182.82 M‬‬
+269.81%
‪‪207.04 M‬‬
+662.09%
‪‪229.67 M‬‬
+218.69%
‪‪313.90 M‬‬
+755.68%
‪‪398.23 M‬‬
+117.82%
‪‪478.95 M‬‬
+131.33%
‪‪1.42 B‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪4.52 M‬‬
‪‪−1.81 M‬‬
‪‪−9.29 M‬‬
‪‪−5.03 M‬‬
‪‪4.08 M‬‬
‪‪−7.84 M‬‬
‪‪−48.15 M‬‬
‪‪−72.14 M‬‬
‪‪−124.05 M‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪76.59 M‬‬
‪‪34.88 M‬‬
‪‪173.54 M‬‬
‪‪202.01 M‬‬
‪‪233.75 M‬‬
‪‪306.05 M‬‬
‪‪350.08 M‬‬
‪‪406.81 M‬‬
‪‪1.30 B‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
Net incomeYoY growth
‪‪76.59 M‬‬
‪‪34.88 M‬‬
‪‪173.54 M‬‬
+251.02%
‪‪202.01 M‬‬
+643.57%
‪‪233.75 M‬‬
+205.20%
‪‪306.05 M‬‬
+777.51%
‪‪350.08 M‬‬
+101.73%
‪‪406.81 M‬‬
+101.38%
‪‪1.30 B‬‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪0.00‬
‪‪76.59 M‬‬
‪‪34.88 M‬‬
‪‪173.54 M‬‬
‪‪202.01 M‬‬
‪‪233.75 M‬‬
‪‪306.05 M‬‬
‪‪350.08 M‬‬
‪‪406.81 M‬‬
‪‪1.30 B‬‬
‪0.17‬
‪0.08‬
‪0.39‬
+250.86%
‪0.45‬
+643.21%
‪0.52‬
+205.17%
‪0.68‬
+777.55%
‪0.78‬
+101.76%
‪0.90‬
+101.38%
‪2.88‬
‪0.17‬
‪0.08‬
‪0.39‬
+250.86%
‪0.45‬
+643.21%
‪0.52‬
+205.17%
‪0.68‬
+777.55%
‪0.78‬
+101.76%
‪0.90‬
+101.38%
‪2.88‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
‪‪450.00 M‬‬
EBITDAYoY growth
‪‪59.42 M‬‬
‪‪27.11 M‬‬
‪‪164.64 M‬‬
+435.79%
‪‪196.88 M‬‬
+2,247.50%
‪‪200.90 M‬‬
+238.12%
‪‪295.79 M‬‬
+991.24%
‪‪387.74 M‬‬
+135.51%
EBITYoY growth
‪‪52.09 M‬‬
‪‪16.96 M‬‬
‪‪154.49 M‬‬
+529.48%
‪‪186.93 M‬‬
+17,518.74%
‪‪190.96 M‬‬
+266.58%
‪‪285.81 M‬‬
+1,585.25%
‪‪377.76 M‬‬
+144.51%
‪‪421.87 M‬‬
+125.68%
‪‪1.28 B‬‬
‪‪−218.19 M‬‬
‪‪−256.22 M‬‬
‪‪−311.55 M‬‬
‪‪−404.12 M‬‬
‪‪−470.35 M‬‬
‪‪−446.50 M‬‬
‪‪−443.86 M‬‬
‪‪−520.92 M‬‬
‪‪−1.88 B‬‬